Literature DB >> 23748096

A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinil.

David J Heal1, Niki W Buckley, Jane Gosden, Nigel Slater, Charles P France, David Hackett.   

Abstract

Lisdexamfetamine dimesylate, which consists of L-lysine covalently bound to D-amfetamine, is the first prodrug for treating ADHD. Its metabolic conversion to yield D-amfetamine by rate-limited, enzymatic hydrolysis is unusual because it is performed by peptidases associated with red blood cells. Other stimulants shown to be effective in managing ADHD include D-amfetamine, methylphenidate and modafinil. All have the potential for misuse or recreational abuse. The discriminative and reinforcing effects of these compounds were determined in rats using a 2-choice, D-amfetamine (0.5 mg/kg, i.p.)-cued drug-discrimination test, and by substitution for intravenous cocaine in self-administration. Lisdexamfetamine (0.5-1.5 mg/kg [D-amfetamine base], p.o.) generalised to saline when tested 15 min post-dosing, but dose-dependently generalised to d-amfetamine at 60 min. At 120 min, its D-amfetamine-like effects were substantially diminished. At 15 min, methylphenidate (3.0-10 mg/kg, p.o.) and D-amfetamine (0.1-1.5 mg/kg, p.o.) dose-dependently generalised to the intraperitoneal D-amfetamine cue. Switching to the intraperitoneal route reduced the interval required for lisdexamfetamine to be recognised as D-amfetamine-like, but did not alter its potency. Switching to intraperitoneal injection increased the potency of methylphenidate and D-amfetamine by 3.4× and 2.2×, respectively. Modafinil (50-200 mg/kg, i.p.) generalised partially, but not fully, to d-amfetamine. Methylphenidate (0.1, 0.3, 1.0 mg/kg/injection, i.v.) maintained robust self-administration at the 2 highest doses. Neither lisdexamfetamine (0.05, 0.15 or 0.5 mg/kg/injection [D-amfetamine base], i.v.) nor modafinil (0.166, 0.498 or 1.66 mg/kg/injection, i.v.) served as reinforcers. The results reveal important differences between the profiles of these stimulants. Lisdexamfetamine did not serve as a positive reinforcer in cocaine-trained rats, and although it generalised fully to D-amfetamine, its discriminative effects were markedly influenced by its unusual pharmacokinetics.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ADHD; AMF; C(max); C-II; C-IV; CD; DAT; Discriminative effects; Drug discrimination; FR; IACUC; IR; Institutional Animal Care and Use Committee; Lisdexamfetamine; Methylphenidate; Modafinil; PET; PFC; Reinforcer; SAL; SR; Schedule 2 Controlled Drug; Schedule 4 Controlled Drug; Self-administration; amfetamine; attention deficit hyperactivity disorder; controlled drug; d-Amfetamine; dopamine reuptake transporter; fixed ratio; i.p.; i.v.; immediate release; intraperitoneal; intravenous; maximum plasma drug concentration; p.o.; per os (oral); positron emission tomography; prefrontal cortex; saline; sustained release; t(max); time to reach maximum plasma drug concentration

Mesh:

Substances:

Year:  2013        PMID: 23748096     DOI: 10.1016/j.neuropharm.2013.05.021

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  21 in total

1.  Treatment with modafinil and escitalopram, alone and in combination, on cocaine-induced effects: a randomized, double blind, placebo-controlled human laboratory study.

Authors:  Christopher D Verrico; Colin N Haile; James J Mahoney; Daisy G Y Thompson-Lake; Thomas F Newton; Richard De La Garza
Journal:  Drug Alcohol Depend       Date:  2014-05-28       Impact factor: 4.492

Review 2.  Monoamine transporter inhibitors and substrates as treatments for stimulant abuse.

Authors:  Leonard L Howell; S Stevens Negus
Journal:  Adv Pharmacol       Date:  2014

3.  Cocaine-like discriminative stimulus effects of phendimetrazine and phenmetrazine in rats.

Authors:  Clayton T Bauer; S Stevens Negus; Bruce E Blough; Matthew L Banks
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

4.  Attenuation of cocaine self-administration by chronic oral phendimetrazine in rhesus monkeys.

Authors:  P W Czoty; B E Blough; T R Fennell; R W Snyder; M A Nader
Journal:  Neuroscience       Date:  2016-03-07       Impact factor: 3.590

5.  Role of d-amphetamine and d-methamphetamine as active metabolites of benzphetamine: Evidence from drug discrimination and pharmacokinetic studies in male rhesus monkeys.

Authors:  Matthew L Banks; Rodney W Snyder; Timothy R Fennell; S Stevens Negus
Journal:  Pharmacol Biochem Behav       Date:  2017-03-31       Impact factor: 3.533

6.  Pilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trial.

Authors:  Marc E Mooney; David V Herin; Sheila Specker; David Babb; Frances R Levin; John Grabowski
Journal:  Drug Alcohol Depend       Date:  2015-06-19       Impact factor: 4.492

7.  Oral modafinil facilitates intracranial self-stimulation in rats: comparison with methylphenidate.

Authors:  Matthew F Lazenka; S Stevens Negus
Journal:  Behav Pharmacol       Date:  2017-06       Impact factor: 2.293

8.  Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.

Authors:  Frances R Levin; John J Mariani; Sheila Specker; Marc Mooney; Amy Mahony; Daniel J Brooks; David Babb; Yun Bai; Lynn E Eberly; Edward V Nunes; John Grabowski
Journal:  JAMA Psychiatry       Date:  2015-06       Impact factor: 21.596

Review 9.  Pharmacokinetic-Pharmacodynamic (PKPD) Analysis with Drug Discrimination.

Authors:  S Stevens Negus; Matthew L Banks
Journal:  Curr Top Behav Neurosci       Date:  2018

10.  Effects of modafinil and R-modafinil on brain stimulation reward thresholds: implications for their use in the treatment of psychostimulant dependence.

Authors:  Brian T Burrows; Lucas R Watterson; Meagan A Johnson; M Foster Olive
Journal:  J Drug Alcohol Res       Date:  2015-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.